An open-label, dose escalation phase 1 study of MLN8237, a novel aurora A kinase inhibitor, in patients with advanced solid tumors.
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Alisertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 11 Sep 2017 Results (n=671) of population PK analysis using patient data from 6 Phase 1, 1 Phase 1/2 and 3 Phase 2 clinical trials published in the British Journal of Clinical Pharmacology
- 06 Dec 2011 Actual patients number (87) added as reported by ClinicalTrials.gov.
- 22 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.